Orion Oyj Class A · OMXHEX:ORNAV
Orion Oyj Class A — 43rd Annual J.P. Morgan Healthcare Conference (January 2025)
16 slides from Orion Oyj Class A's conference presentation, Jan 16, 2025
Slide 1: The road is open for growth
Orion Pharma The road is open for growth 43rd Annual J.P. Morgan Healthcare Conference 16 January 2025
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Orion today – building well-being since 1917
Orion today – building well-being since 1917 Diversified R&D focus in pharmaceutical company oncology and pain ~3,600 employees Operations in more than 35 countries Net sales1 EUR 1,429 million Impacting millions of Operating profit1 417 million lives globally 3 Investor Presentation © Orion Corpora
Slide 4: Our diversified and balanced businesses
Our diversified and balanced businesses Innovative Generics and Branded Products Animal Health Fermion Medicines Consumer Health Respiratory Companion API Portfolio CNS 300+ products animals & manufacturing highlights Women’s Health livestock & CDMO Nordics & Geographies Global Europe & APAC Global
Slide 5: With strong track record in delivering financial results, we have entered a new growth era
With strong track record in delivering financial results, we have entered a new growth era Net sales Operating profit (EUR million) (EUR million) +11.1% 1,500 1,429 500 1,341 440 130 417 1,190 228 400 1,078 30 1,051 1,041 45 28 130 1,000 228 +7.7% 300 280 275 253 28 243 30 45 1,299 1,160 200 +16.4%
Slide 6: From local to global step by step
From local to global step by step 4 5 1 2 1. 2008-2011: Southern Europe 2. 2020: Thailand, Singapore & Malesia 3. 2021: Australia & New Zealand 4. 2023: R&D Hub in USA 3 5. 2024: Japan Sales operations Production and supply chain operations 6 R&D operations Back-office operations
Slide 7: Geographic split has become more balanced
Geographic split has become more balanced Net sales split by geography, EUR million Net sales split by geography, % 1,429 1,341 214 15% 12% 13% 14% 11% 15% 15% 142 1,190 6% 10% 8% 9% 1,051 1,078 1,041 173 25% 15% 977 335 315 22% 129 135 141 148 83 175 31% 34% 103 90 32% 34% 58 31% 368 400 30% 28% 33
Slide 8: Innovative Medicines short and mid-term growth driven by key assets Nubeqa and opevesostat
Innovative Medicines short and mid-term growth driven by key assets Nubeqa® and opevesostat Net sales 409 (EUR million) 60 Nubeqa® Opevesostat 315 70 Partner Partner 213 228 30 Annually tiered royalty Annually tiered royalty from Annual average now >20%, low double-digit to low with EUR 3 billion in
Slide 9: Branded Products build on innovative legacy products with Easyhaler leading the way
Branded Products build on innovative legacy products with Easyhaler® leading the way 279 280 163 261 13.7% 144 130 115 117 105 130 90 163 77 144 64 EUR million 51 113 EUR million 88 82 2015 2016 2017 2018 2019 2020 2021 2022 2023 LTM Q3 2024 28 21 23 2022 2023 LTM Q3 2024 Easyhaler® Divina® series E
Slide 10: We have a long history of bringing innovative treatments to market
We have a long history of bringing innovative treatments to market Nubeqa® reached blockbuster status in Proprietary human pharmaceuticals developed by Orion September 2024 1993 1998 2000 2003 2011 2018 1988 1994 1999 2002 2004 2014 2019 10 Investor Presentation © Orion Corporation
Slide 11: Key clinical development pipeline
Key clinical development pipeline Partner Project/compound Indication PHASE I PHASE II PHASE III REGISTRATION ARANOTE / darolutamide Prostate cancer (mHSPC) Ongoing ARASTEP / darolutamide Prostate cancer (BCR) OMAHA1 / opevesostat Prostate cancer (mCRPC) OMAHA2a / opevesostat Prostate cancer (mCRPC)
Slide 12: ODM-105 (tasipimidine) – a novel treatment for insomnia
ODM-105 (tasipimidine) – a novel treatment for insomnia Why insomnia? Huge unmet need ODM-105 has potential to differentiate • Insomnia is underdiagnosed and undertreated ODM-105 expectations – aiming to • Current medications have shortcomings be first-in-class treatment • Insomnia with co-morbiditi
Slide 13: ODM-212 – a TEAD inhibitor with best-in-class potential
ODM-212– a TEAD inhibitor with best-in-class potential Mode of action ODM-212 has potential to be best-in-class • Dysregulation of Hippo pathway can lead to tumor growth, Evidence of clinical benefit (tumor shrinkage) metastasis and resistance to several cancer therapies Efficacy already in dose esc
Slide 14: Financial objectives
Financial objectives Strategy period 2024–2028 Net sales Operating profit CAGR ≥8%1 To grow faster than net sales1,2 Equity ratio Return on equity (ROE) ≥50% ≥25% Dividend Annually increasing dividend – payout ratio 50%–100% 1 Base year 2023 2 Without EUR 30.7 million positive impact from the transf
Slide 15: Key takeaways
Key takeaways GROWTH INNOVATION STABILITY Nubeqa® and opevesostat Long history and proven track Diversified businesses make a near term drivers and record in innovation solid foundation opportunities Oncology and pain areas of Proven track record in Long-term growth focus delivering financial result
Slide 16: Q&A
Q&A Visit us at https://www.orion.fi/en/investors/ For more information about Orion as an investment 16
Orion — 43rd Annual J.P. Morgan Healthcare Conference (January 2025) on 6ix